Detection of non-Hodgkin's lymphoma liver disease in cirrhotic patients by PICARDI, MARCO et al.
Haematologica 1999; 84:278-288 scientific correspondence
Detection of non-Hodgkin’s lymphoma liver
disease in cirrhotic patients
Sir,
Computer tomography (CT) scan and ultrasound
scan (US) are the preferred methods for staging sub-
diaphragmatic non-Hodgkin’s lymphoma (NHL),1
but their sensitivity in detecting focal lesions in the liv-
er may be reduced if fibrosis is present. We investi-
gated 6 NHL patients who also had a viral liver dis-
ease (chronic active hepatitis or cirrhosis) by US and
CT liver scans and liver biopsy. US was performed
using a Spazio-Hitachi instrument with a 3.5 MHz
probe. With the exception of two patients, who
underwent laparotomy as a diagnostic procedure, liv-
er biopsy was performed under US guidance using a
Menghini fine needle with automatic aspiration (1.2
mm in diameter x 150 mm in length), or a Chiba fine
needle (0.7 mm x 150 mm). The needle crossed the
focal lesion for at least 3 cm, thus also exploring the
surrounding hepatic tissue. In patient #6, with no
evidence of focal lesions, the biopsy was carried out
in the left hepatic lobe. In all patients prothrombin
time prolongation was ≤ 5 seconds with respect to
control plasma and platelet count was ‡ 50,000/µL.
The immunohistochemistry panel included LCA,
CD20, CD45RO and CD3; in three patients, the pres-
ence of clonal B-lymphocytes was assessed by light
chain restriction.
Table 1 summarizes our data. US showed focal
lesions in three patients, while CT scan detected focal
lesions in one patient and none in the remaining (Fig-
ure 1). US-guided biopsies were well tolerated and
uncomplicated. The samples, obtained by a single pass
of the needle, measured about 1 mm in diameter and
had a length of 25-40 mm; they were all informative,
changing the stage in 5/6 patients. Histology docu-
mented severe chronic active hepatitis  in two patients
and overt cirrhosis in four; 5/6 patients (all HCV+)
showed NHL involvement, as suggested by an excess of
B cells and proved by light chain restriction in three of
them. The single HBsAg+ patient  had increased
transaminases without evidence of focal lesions; liver
histology excluded involvement by lymphoma. 
As in patients with hepatocellular carcinoma,2 even
in this small series of NHL patients, US proved more
accurate than CT scan in identifying small (≤ 1 cm)
focal lesions in cirrhotic livers. However, diffuse lym-
phoma involvement can only be detected by biopsy.
An US-guided fine needle biopsy can substitute more
invasive methods such as  larger cutting needle biop-
Figure 1.
A. Ultrasound scan of patient #4, showing small nodular hypoechoic lesions (arrows) in the context of a fibrotic liver.
B. Liver CAT scan of the same patient, showing no detectable focal lesions. The spleen was previously ablated.
Liver biopsy of the same patient, which stained positive for CD20 (C) and k (D), and was negative for l (E).
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sy (diameter 1.8-2.0 mm) or laparoscopic/laparo-
tomic biopsy.
A majority of our patients had HCV-related liver
disease. Recent reports have stressed the association
between HCV infection and B-cell NHL.3-8 In our
small series of HCV+ patients the liver seems an
exceedingly frequent extranodal target for NHL cells,
considering that less than 10% of unselected NHL
patients show liver involvement. We may speculate
that a pre-existing non-clonal lymphoid infiltration
may favor a subsequent localization of clonal cells.
We treated our patients with standard chemother-
apy regimens: 5 patients received CHOP-like regi-
mens and one MACOP-B and DHAP followed by
autologous transplantation. Three patients are expe-
riencing a prolonged disease free survival (Table 1).
Thus, it seems that the coexistent HCV infection does
not affect overall survival of NHL patients, as already
noticed in patients with low-grade lymphoma.9 Our
observations deserve further investigation in larger
cohorts of patients in order to define the prognostic
profile and the optimal management of patients with
NHL and virus-induced liver disease.
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Table 1. Patient characteristics, liver imaging, histological findings and outcome.
Pt. Sex/ Type of liver NHL Disease status, US CT Biopsy Liver involvement by NHL CHT CR OS
age disease grade* clinical stage procedure B cell LC mo.
used excess restriction
1 M/73 HCV+ cirrhosis I staging, II B small (≤ 1 cm) nodular no focal lesion US-FNAB yes not done CEOP yes 15+
hypoechoic lesions
2 F/54 HCV+ cirrhosis H diagnosis, IIE A no focal lesion same as US laparotomy yes k VICED° yes 18+
3 F/53 HCV+ cirrhosis I diagnosis, IIS B no focal lesion same as US laparotomy yes k CEOP yes 22+
4 F/55 HCV+ CAH    L follow-up, III B small (≤ 1 cm) nodular no focal lesion US-FNAB yes k CEOP no 1#
hypoechoic lesions
5 F/57 HCV+ cirrhosis I relapse, II B large (‡ 3 cm) nodular same as US US-FNAC yes not done VICED° no 1#
hypoechoic lesions CEOP
6 M/32 HBsAg+ CAH H restaging, IV B no focal lesion same as US US-FNAB no no MACOP-B no 6#
DHAP
a BMT
*according to the Working Formulation: L = low; I = intermediate; H = high; US = ultrasound scan; CT = computer tomography; LC = light chain; CHT = chemotherapy regi-
mens;  CR = complete remission; OS = overall survival, months; US-FNAB = ultrasound-guided Menghini cutting fine needle biopsy; US-FNAC = ultrasound-guided Chiba fine
needle biopsy; CAH = chronic active hepatitis; #= deceased of lymphoma progression; °a CHOP-like regimen with the addition of etoposide (10).
